These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 15562745)
21. Serosurvey of measles, mumps and rubella antibodies in Saudi children. Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981 [TBL] [Abstract][Full Text] [Related]
23. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ; Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432 [TBL] [Abstract][Full Text] [Related]
24. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R; Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189 [TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Black S; Friedland LR; Schuind A; Howe B; Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769 [TBL] [Abstract][Full Text] [Related]
26. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Marshall H; Nolan T; Roberton D; Richmond P; Lambert S; Jacquet JM; Schuerman L Vaccine; 2006 Aug; 24(35-36):6120-8. PubMed ID: 16822597 [TBL] [Abstract][Full Text] [Related]
28. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001 [TBL] [Abstract][Full Text] [Related]
29. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Dos Santos BA; Ranieri TS; Bercini M; Schermann MT; Famer S; Mohrdieck R; Maraskin T; Wagner MB Rev Panam Salud Publica; 2002 Oct; 12(4):240-6. PubMed ID: 12431355 [TBL] [Abstract][Full Text] [Related]
30. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529 [TBL] [Abstract][Full Text] [Related]
31. Reporting of adverse events following immunization in Australia. Isaacs D; Lawrence G; Boyd I; Ronaldson K; McEwen J J Paediatr Child Health; 2005 Apr; 41(4):163-6. PubMed ID: 15813867 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. Cassidy WM; Jones G; Williams K; Deforest A; Forghani B; Virella G; Venters C J Adolesc Health; 2005 Mar; 36(3):187-92. PubMed ID: 15737773 [TBL] [Abstract][Full Text] [Related]
34. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children. Bernsen RM; van der Wouden JC Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826 [TBL] [Abstract][Full Text] [Related]
35. The use of a computerized database to monitor vaccine safety in Viet Nam. Ali M; Canh GD; Clemens JD; Park JK; von Seidlein L; Minh TT; Thiem DV; Tho HL; Trach DD; Bull World Health Organ; 2005 Aug; 83(8):604-10. PubMed ID: 16193545 [TBL] [Abstract][Full Text] [Related]
36. [Adverse effects following vaccinations and effectiveness of different live vaccines against mumps]. Magdzik W; Zieliński A Przegl Epidemiol; 2002; 56(3):377-89. PubMed ID: 12608087 [TBL] [Abstract][Full Text] [Related]
37. Aseptic meningitis after vaccination with L-Zagreb mumps strain-virologically confirmed cases. Faulty calculation of rates. Kaic B Vaccine; 2007 Jan; 25(7):1159-60. PubMed ID: 17092613 [TBL] [Abstract][Full Text] [Related]
38. Developing an immunization safety surveillance system in the Philippines. Hartigan-Go K; Roces MC; Habacon CA; Mansoor O; Shin S Bull World Health Organ; 2000; 78(9):1166. PubMed ID: 11019466 [No Abstract] [Full Text] [Related]
39. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Jacobsen SJ; Ackerson BK; Sy LS; Tran TN; Jones TL; Yao JF; Xie F; Cheetham TC; Saddier P Vaccine; 2009 Jul; 27(34):4656-61. PubMed ID: 19520201 [TBL] [Abstract][Full Text] [Related]
40. Humoral and cellular immune response after measles vaccination in Taiwan. Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]